PARTNERS & DONORS
For work package 4, DiTECT-HAT works in close collaboration with Drugs for Neglected Diseases initiative (DNDi). DNDi is a collaborative non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, amongst others for human African trypanosomiasis. In fact, so far DNDi is the only organization performing therapeutic trials for human African trypanosomiasis. In 2016, DNDi launches a therapeutic phase II/III study (DNDi-OXA-02-HAT) testing a new oral single dose drug, SCYX-7158. Combination of DiTECT-HAT work package 4 with the SCYX-7158 study allows evaluation of new treatment outcome assessment markers during follow-up without the need for additional lumbar or venipunctures.
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials. EDCTP funds the DiTECT-HAT project.
HAT platform: The HAT platform builds and strengthens treatment methodologies and clinical trial capacity in sleeping sickness-endemic countries, and encourages the sharing of information and strengthening of ties among endemic countries.
WHO: The world Helath Organization directs and coordinates international health within the United Nations’ system. For HAT, WHO’s objective is the elimination of human African trypanosomiasis as a public health problem and the establishment of a sustained surveillance system in all disease-endemic countries. To achieve this, the HAT control and surveillance programme focuses on accessibility of people at risk to diagnosis and treatment, strengthened control and surveillance, Guidelines and policies.
Trypanogen: TrypanoGEN is a international collaborative research network focussing on human susceptibility to African trypanosomiasis.
Find: FIND is an international non-profit organization that enables the development and delivery of diagnostic tests for poverty-related diseases, including tuberculosis, malaria, sleeping sickness, hepatitis C, HIV, leishmaniasis, Buruli ulcer and Chagas disease.
Nidiag: NIDIAG is a European research network (collaborative project) supported by the European Commission under the 7th framework program. Its aim is to bridge the gap between existing technological innovation in diagnostics and clinical care practice for NID in resource-poor settings. The specific objectives are to develop simple, cost-effective diagnosis-treatment algorithms for three NID-related clinical syndromes: the persistent fever, the neurological and the digestive syndromes.